Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Toll Free Number 1-888-577-8839
Trialsites@msd.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Back

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Recruiting

Open to: ALL

Age: 12.0 - N/A

Cambridge Glasgow London London

Medical Conditions

Neoplasms
Neuroendocrine Tumors
Gastrointestinal Stromal Tumors
Pheochromocytoma
Adenoma, Islet Cell
Paraganglioma
Von Hippel-Lindau Disease

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2021 Jun 2029

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.

Intervention Arm Group : Belzutifan;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Addenbrooke's Hospital ( Site 1309)
    Cambridge
    Cambridgeshire
    CB2 2QQ
  • The Beatson West of Scotland Cancer Centre ( Site 1308)
    Glasgow
    Glasgow City
    G12 0YN
  • Hammersmith Hospital-Medical Oncology ( Site 1304)
    London
    London, City Of
    W12 OHS
  • Royal Free Hospital ( Site 1302)
    London
    England
    NW3 2QG

Toll Free Number 1-888-577-8839
Trialsites@msd.com



The study is sponsored by Merck Sharp & Dohme LLC



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04924075
Last updated 17 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top